Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | YES1 | P07947 | 3/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630415 | 0.89 | EGFR (0.53) | MAPK1AURKBMAPTRAB9ANPC1 | |
| SCHEMBL629467 | 0.87 | EGFR (0.61) | MAPK1AURKBABL1PIM1MAPT | |
| SCHEMBL629420 | 0.86 | EGFR (0.52) | MAPK1AURKBABL1PIM1MAPT | |
| SCHEMBL629365 | 0.85 | EGFR (0.54) | MAPK1AURKBABL1PIM1MAPT | |
| SCHEMBL630200 | 0.83 | RAB9A (0.53) | MAPK1AURKBMAPTRAB9ANPC1 | |
| SCHEMBL629296 | 0.82 | MAPK1 (0.46) | MAPK1AURKBABL1PIM1EGFR | |
| SCHEMBL629413 | 0.81 | EGFR (0.49) | MAPK1AURKBABL1MAPTRAB9A | |
| SCHEMBL629397 | 0.80 | EGFR (0.51) | MAPK1AURKBMAPTRAB9ANPC1 | |
| SCHEMBL629704 | 0.79 | ABL1 (0.45) | MAPK1AURKBABL1PIM1EGFR | |
| SCHEMBL630518 | 0.79 | AURKB (0.61) | MAPK1AURKBABL1PIM1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419411-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | Æterna Zentaris GmbH (DE) | 2012-02-22 | — | — | EP | claimed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | claimed |
| EP-2241557-A1 | Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses | Æterna Zentaris GmbH (DE) | 2010-10-20 | — | — | EP | claimed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | claimed |
| US-9340526-B2 | Process for preparing pyridyl-substituted pyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20150191447-A1 | Process for Preparing Pyridyl-Substituted Pyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-09 | — | — | US | disclosed |
| US-8987460-B2 | Process for preparing pyridyl-substituted pyrazoles | BAYER CROPSCIENCE AG (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2414345-B1 | Method for manufacturing Pyridyl-substituted pyrazoles | BAYER CROPSCIENCE AG (DE) | 2014-09-17 | — | — | EP | disclosed |
| US-20130131347-A1 | Process for Preparing Pyridyl-Substituted Pyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| EP-2243777-A1 | Method for manufacturing Pyridyl-substituted pyrazoles | Bayer CropScience AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2241557-A1 | Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses | Æterna Zentaris GmbH (DE) | 2010-10-20 | — | — | EP | disclosed |
| EP-2241557-A1 | Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses | Æterna Zentaris GmbH (DE) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131347-A1 | Process for Preparing Pyridyl-Substituted Pyrazoles | PDXK, PLK2, WNK3 | MAPK1 744/4885AURKB 107/4885ABL1 1278/4885 |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | NQO2, G6PD, GLS2 | MAPK1 2140/4885AURKB 2506/4885ABL1 531/4885 |
| US-20150191447-A1 | Process for Preparing Pyridyl-Substituted Pyrazoles | PDXK, PLK2, WNK3 | MAPK1 744/4885AURKB 107/4885ABL1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.